Navigation Links
Mast Therapeutics Reports First Quarter 2013 Financial Results
Date:5/15/2013

ther regulatory agencies may determine they are not sufficient to support a new drug application; the risk that even if clinical studies of MST-188 in one indication or jurisdiction are successful, clinical studies in another indication or jurisdiction may not be successful; the potential for unsuccessful nonclinical or clinical studies in one indication or jurisdiction, or by a future partner that may be outside of the Company's control, to adversely affect opportunities for MST-188 in other indications or jurisdictions; the Company's reliance on contract research organizations (CROs), contract manufacturing organizations (CMOs), and other third parties to assist in the conduct of important aspects of development of MST-188, including clinical studies, and regulatory activities for MST-188 and that such third parties may fail to perform as expected; the Company's ability to obtain additional funding on a timely basis or on acceptable terms, or at all; the potential for the Company to delay, reduce or discontinue current and/or planned development activities, including clinical studies, partner MST-188 at inopportune times or pursue less expensive but higher-risk and/or lower return development paths if it is unable to raise sufficient additional capital as needed; the risk that acceptable partnering opportunities for MST-188 may not be available in particular jurisdictions or indications and, consequently, the Company may not be able to pursue development of MST-188 in certain jurisdictions and indications; the risk that the FDA or any other regulatory agency does not grant marketing approval of MST-188, on a timely basis, or at all; the risk that the Company is not able to adequately protect its intellectual property rights relating to the MAST platform and MST‑188 and prevent competitors from duplicating or developing equivalent versions of its product candidates, including MST-188; and other risks and uncertainties more fully described in the Company's pre
'/>"/>
SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 ... for Enterprise, having more than doubled its overseas sales ... PharmaGenesis today celebrates winning the Queen,s Award for Enterprise, ... is the world,s first HealthScience Communications consultancy, helping its ... of patient need. Having more than doubled its exports ...
(Date:4/21/2015)... Cardiologists at Henry Ford Hospital have implanted a device that ... heartbeat. With only handful of hospitals in the ... to add another option to its arsenal of tools for ... to pump. "This is a first in ... at a non-clinical trial site," says cardiologist Claudio Schuger ...
(Date:4/21/2015)... , April 21, 2015  St. Vincent ... to patient care. Already following strict disinfection routines, ... Tru-D SmartUVC to eliminate harmful germs, like Ebola, ... and norovirus that can infect patients during their ... Logo - http://photos.prnewswire.com/prnh/20150420/199749LOGO ...
Breaking Medicine Technology:Queen's Award Crowns Achievements of Local Consultancy 2Queen's Award Crowns Achievements of Local Consultancy 3Queen's Award Crowns Achievements of Local Consultancy 4Queen's Award Crowns Achievements of Local Consultancy 5Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 2Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 3St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 2St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 3
... NEW YORK, April 14, 2011 Dr. David Samadi, Vice ... at The Mount Sinai Medical Center in New York City , ... month in the British Medical Journal ( ... 1,500 of whom were screened for prostate cancer every ...
... Calif., April 14, 2011 Freedom Innovations, a ... technology lower extremity prosthetic devices, today announced a ... exclusive rights to commercialize the world,s first lower ... joints that operate synergistically.  Developed at the Vanderbilt ...
Cached Medicine Technology:Does Prostate Cancer Screening Reduce Mortality Rates? 2Does Prostate Cancer Screening Reduce Mortality Rates? 3Does Prostate Cancer Screening Reduce Mortality Rates? 4Freedom Innovations to Commercialize the World's First Actively-Powered, Complete Lower Extremity Prosthesis 2Freedom Innovations to Commercialize the World's First Actively-Powered, Complete Lower Extremity Prosthesis 3
(Date:4/21/2015)... 2015 AvePoint, the established ... today announced a new enhancement to DocAve Policy ... Office 365 Management Activity API. This integration creates a ... and take action on all events that take place ... 365 Management Activity API provides customers with greater transparency ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Wireless ... services, has been recognized by the Boston Business Journal ... The ranking was announced at a recent event celebrating ... list of the fastest-growing private companies in Massachusetts. , ... in the state that recorded the fastest revenue growth ...
(Date:4/21/2015)... April 21, 2015 Lowcostcarinsuranceprice.com has released a ... auto insurance for SUVs. , SUVs are large ... collision between an SUV and a smaller regular car shows ... of surviving. This makes SUV safer in crashes, but these ... in certain situation. , It is now possible to ...
(Date:4/21/2015)... The report “Dermatitis – ... on the therapeutic development for Dermatitis. ... new targets and MOAs to produce first-in-class ... is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html . ... involved in the therapeutic development for Dermatitis ...
(Date:4/21/2015)... has released a new blog post presenting heavily circulated ... insurance prices . , Commuting on heavy circulated ... their insurance options before deciding what plan to buy. ... of the popular policies provide liability, collision or comprehensive ... find the best prices in their area simply by ...
Breaking Medicine News(10 mins):Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 2Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 3Health News:Wireless Analytics Ranked as 25th Fastest Growing Private Company in Massachusetts 2Health News:Auto Insurance Quotes For SUVs Are Available Online 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2
... hair loss in people as young as 16 whereas the phenomenon ... ,"Nobody can escape stress in modern day life. Stress ... the thinning of hair," Mumbai-based Sonal Shah said. ,"Initially, ... has come down to as low as 16 and 18," Shah ...
... State University are pumping for a controversial theory, which ... into "dark states" where they can be easily dismantled ... some of the most accepted theories in biochemistry. ... by much of the science community, has just in ...
... to reconstruct a complex molecular system of Darwinian evolution for ... genes. ,The research was led by ... Oregon's Center for Ecology and Evolutionary Biology, and will be ... selection can drive the evolution of complex molecular systems – ...
... a study conducted by the University of Erfurt in ... to inflict financial pain to achieve// collective gain. The ... ,Researchers have found that groups in which ... more popular than groups without this option. Though two ...
... at a high risk for developing Alzheimer's disease would benefit ... ibuprofen. This therapy appears to be of maximum benefit in ... is a high-risk condition predisposing them to Alzheimer's disease. ... Baltimore monitored nearly 5000 elderly residents of Cache County in ...
... lymphatic leukemia and dementia, was a regular with a day unit ... mentally decrepit clients. An ambulance team was in charge of picking ... at the residence. ,On August 20th 2003, the ambulance, ... door of an empty house of another patient, after a key ...
Cached Medicine News:Health News:Stress Can Cause Hair loss at 16 2Health News:Controversial Theory Says DNA Can Be Pushed To "Dark States" 2Health News:Controversial Theory Says DNA Can Be Pushed To "Dark States" 3Health News:Scientists Explain Complex Darwinian Evolution 2Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 2Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 3Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 4
... The S7 gives enhanced deliverability ... Platform gives your short-wire capability and ... catheters. Secure Technology Stent Retention ... Discrete Technology designed to minimize balloon ...
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
A fusion of first class deliverability, acute angiographic results and excellent versatility....
Medicine Products: